- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Advances in Urology
Volume 2012 (2012), Article ID 429213, 10 pages
A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges
1Section of Experimental Oncology, Leeds Institute of Molecular Medicine, St James’s University Hospital, Leeds LS9 7TF, UK
2Institute of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, UK
Received 31 May 2012; Accepted 17 June 2012
Academic Editor: Nan-Haw Chow
Copyright © 2012 Erica di Martino et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Citations to this Article [10 citations]
The following is the list of published articles that have cited the current article.
- S. V. Williams, C. D. Hurst, and M. A. Knowles, “Oncogenic FGFR3 gene fusions in bladder cancer,” Human Molecular Genetics, vol. 22, no. 4, pp. 795–803, 2012.
- C. G. Stoehr, R. Stoehr, A. Rogler, K. Amann, R. Knuechel-Clarke, and A. Hartmann, “Personalized urooncology based on molecular uropathology. Part 1: What is diagnostic routine?,” Urologe, vol. 52, no. 7, pp. 970–975, 2013.
- Shirish M. Gadgeel, Wei Chen, Michele L. Cote, Aliccia Bollig-Fischer, Susan Land, Ann G. Schwartz, and Gerold Bepler, “Fibroblast Growth Factor Receptor 1 Amplification in Non-Small Cell Lung Cancer by Quantitative Real-Time PCR,” Plos One, vol. 8, no. 11, 2013.
- Artur A. Belov, and Moosa Mohammadi, “Molecular Mechanisms of Fibroblast Growth Factor Signaling in Physiology and Pathology,” Cold Spring Harbor Perspectives In Biology, vol. 5, no. 6, 2013.
- Yann Neuzillet, Bas W. G. van Rhijn, Nadia L. Prigoda, Bharati Bapat, Liyang Liu, Peter J. Bostrom, Neil E. Fleshner, Brenda L. Gallie, Alexandre R. Zlotta, Michael A. S. Jewett, and Theo H. van der Kwast, “FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer,” Virchows Archiv, 2014.
- A. Hartmann, T. Schlomm, S. Bertz, J. Heinzelmann, S. Hölters, R. Simon, R. Stoehr, and K. Junker, “Prognostische und prädiktive molekulare Marker urologischer Tumoren,” Der Urologe, vol. 53, no. 4, pp. 491–500, 2014.
- Meilin Wang, Haiyan Chu, Qiang Lv, Li Wang, Lin Yuan, Guangbo Fu, Na Tong, Chao Qin, Changjun Yin, Zhengdong Zhang, and Jianfeng Xu, “Cumulative effect of genome-wide association study-identified genetic variants for bladder cancer,” International Journal of Cancer, 2014.
- Nicole Schweiger, Marlene Hauck, Heinrich Steinhoff, Sandra Sampl, Martin Reifinger, Ingrid Walter, Theresa Kreilmeier, Brigitte Marian, Michael Grusch, Walter Berger, Klaus Holzmann, and Miriam Kleiter, “Canine and human sarcomas exhibit predominant FGFR1 expression and impaired viability after inhibition of signaling,” Molecular Carcinogenesis, 2014.
- Deyao Wu, Yunfeng Zhou, Huixing Pan, Jian Zhou, Yuanfeng Fan, and Ping Qu, “microRNA-99a inhibiting cell proliferation, migration and invasion by targeting fibroblast growth factor receptor 3 in bladder cancer,” Oncology Letters, vol. 7, no. 4, pp. 1219–1224, 2014.
- Rosa Nadal, “New Treatments for Bladder Cancer: When Will We Make Progress?,” Current Treatment Options in Oncology, vol. 15, no. 1, pp. 99–114, 2014.